[ad_1]
- Hengrui Medicine (600276.SH) and the company’s directors and supervisors have no violations of laws and regulations. Currently there are no relevant lawsuits.
- The Hengrui Medicine bribery chain is off to a great start: the director of the city’s third-tier department of anesthesiology can take 3.31 million bribes.
- Hengrui Pharmaceutical’s bribery scandal behind the “toxin tumor” of pharmaceutical industry gold sales will be removed
- Hengrui Medicine participates in the director of the anesthesiology department 3.31 million marketing costs of bribery cases will eventually be transferred to patients
- See full story on Google News
